T-DXd HER2-zero Gastric — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — TA879 made no recommendation following absence of a company evidence submission
TA879 was terminated without a recommendation because the company did not submit evidence. That is different from a positive restricted recommendation or a clinical finding of no activity. A medicine’s licence or biologic plausibility does not by itself create a NICE-funded routine NHS indication.
Reference: NICE TA879: trastuzumab deruxtecan for HER2-positive advanced gastric cancer. https://www.nice.org.uk/guidance/ta879